Marja Liisa Dahl

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Marja-Liisa Dahl är professor i klinisk farmakologi vid institutionen för laboratoriemedicin, avdelningen för klinisk farmakolog vid Karolinska Institutet sedan 2012. Hon är också funktionsområdeschef vid medicinsk enhet klinisk farmakologi, Karolinska Universitetssjukhuset.

Artiklar

Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2026;82(2):57
Prescribed drugs and comorbidities as risk factors for Torsades de Pointes arrhythmia: a Swedish population-based cohort study
Andersson ML; Fastbom J; Danielsson B; Wikstrom E; Dahl M-L; Nowinski K
Article: SCIENTIFIC REPORTS. 2025;15(1):24918
CYP2D6-inhibiting drugs and risk of fall injury after newly initiated therapy with beta-blockers-a register-based case-crossover study
Leander K; Dahl M-L; Vikstrom M; Moller J; Soederberg-Lofdal K
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2025;91(2):464-478
Sub- and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study
Soeria-Atmadja S; Amuge P; Nanzigu S; Bbuye D; Eriksen J; Rubin J; Kekitiinwa A; Obua C; Dahl M-L; Bergstrand MP; Pohanka A; Gustafsson LL; Naver L
Article: INTERNATIONAL JOURNAL OF QUALITATIVE STUDIES ON HEALTH AND WELL-BEING. 2024;19(1):2292826
Lived experiences of closeness to a person using Anabolic androgenic steroids a next of kin perspective
Borjesson A; Ekebergh M; Dahl M-L; Ekstrom L; Lehtihet M; Vicente V
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2024;90(11):2823-2836
CYP2B6 and ABCB1 genotypes predict methadone plasma exposure among patients on maintenance therapy against opioid addictions in Tanzania
Mugusi S; Mnkugwe RH; Sanga AA; Salahuddin A; Barclay V; Shayo G; Dahl M-L; Aklillu E
Article: SCIENTIFIC REPORTS. 2024;14(1):11730
CYP2C19 and CYP2J2 genotypes predict praziquantel plasma exposure among Ethiopian school-aged children
Gebreyesus TD; Makonnen E; Telele NF; Barry A; Mnkugwe RH; Gerba H; Dahl M-L; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023;79(9):1261-1269
Medicines postpartum in Sweden and coverage in Janusmed Breastfeeding
Asplund AB; Skold PD; Lind LK; Cesta CE; Dahl ML; Jonsson EW; Andersson ML
Article: DRUGS & AGING. 2023;40(4):369-376
Pharmacological Risk Assessment Among Older Patients with Polypharmacy Using the Clinical Decision Support System Janusmed Risk Profile: A Cross-Sectional Register Study
Petersson L; Schoergenhofer C; Askfors Y; Justad H; Dahl M-L; Andersson MLL
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2022;130(4):492-500
Plasma concentrations of methylphenidate enantiomers in adults with ADHD and substance use disorder, with focus on high doses and relationship to carboxylesterase activity
Arvidsson M; Franck J; Ackehed G; Bergstrand MP; Ekstrom L; Rosenborg S; Dahl M-L
Article: FRONTIERS IN REPRODUCTIVE HEALTH. 2021;3:787954
A Summary of Online Enquiries Submitted to Anti-doping Hotline 2005-2018
Ekstrom L; Brostrom S; Dahl M-L; Borjesson A
Article: FRONTIERS IN SPORTS AND ACTIVE LIVING. 2021;3:656413
Women's Experiences of Using Anabolic Androgenic Steroids
Boerjesson A; Ekebergh M; Dahl M-L; Ekstroem L; Lehtihet M; Vicente V
Article: SCIENTIFIC REPORTS. 2021;11(1):5796
CYP2D6-inhibiting drugs and risk of fall injuries after newly initiated antidepressant and antipsychotic therapy in a Swedish, register-based case-crossover study
Dahl M-L; Leander K; Vikstrom M; Frumerie C; Nordenmalm S; Moller J; Soderberg-Lofdal K
Article: INTERNATIONAL JOURNAL OF QUALITATIVE STUDIES ON HEALTH AND WELL-BEING. 2021;16(1):1927490
Men′s experiences of using anabolic androgenic steroids
Borjesson A; Ekebergh M; Dahl M-L; Ekstrom L; Lehtihet M; Vicente V
Article: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 2020;13(9):925-934
Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet
Hoffmann M; Vander Stichele R; Bates DW; Bjorklund J; Alexander S; Andersson ML; Auraaen A; Bennie M; Dahl M-L; Eiermann B; Hackl W; Hammar T; Hjemdahl P; Koch S; Kunnamo I; Le Louet H; Panagiotis P; Raego L; Spedding M; Seidling HM; Demner-Fushman D; Gustafsson LL
Article: MEDICINA-LITHUANIA. 2020;56(6):E265-265
Male Anabolic Androgenic Steroid Users with Personality Disorders Report More Aggressive Feelings, Suicidal Thoughts, and Criminality
Borjesson A; Moller C; Hagelin A; Vicente V; Rane A; Lehtihet M; Dahl M-L; Garevik N; Ekstrom L
Article: DRUG TESTING AND ANALYSIS. 2020;12(4):514-523
Studies of athlete biological passport biomarkers and clinical parameters in male and female users of anabolic androgenic steroids and other doping agents
Borjesson A; Lehtihet M; Andersson A; Dahl M-L; Vicente V; Ericsson M; Ekstrom L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2020;76(2):229-237
Pharmacokinetics of methylphenidate and ritalinic acid in plasma correlations with exhaled breath and oral fluid in healthy volunteers
Arvidsson M; Dahl M-L; Beck O; Ackehed G; Nordin K; Rosenborg S
Article: NORDIC JOURNAL OF PSYCHIATRY. 2019;73(2):118-124
Methylphenidate effects on processing speed in a clinical sample of adults with ADHD and substance use disorder: a pilot study
Arvidsson M; Dahl M-L; Franck J; Wiig EH; Nielsen NP
Article: DRUG TESTING AND ANALYSIS. 2019;11(1):27-32
Drug abuse screening with exhaled breath and oral fluid in adults with substance use disorder
Arvidsson M; Ullah S; Franck J; Dahl M-L; Beck O
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2018;74(6):843-851
Clinical pharmacology in Stockholm 50 years-report from the jubilee symposium
Eichelbaum M; Dahl M-L; Sjoqvist F
Visa fler

Alla övriga publikationer

Letter: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2026;82(4):90
Risk drugs and comorbidities in patients with torsade de pointes
Andersson ML; Fastbom J; Danielsson B; Wikstrom E; Dahl M-L; Nowinski K
Review: WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY. 2021;22(8):561-628
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants
Eap CB; Grunder G; Baumann P; Ansermot N; Conca A; Corruble E; Crettol S; Dahl ML; de Leon J; Greiner C; Howes O; Kim E; Lanzenberger R; Meyer JH; Moessner R; Mulder H; Muller DJ; Reis M; Riederer P; Ruhe HG; Spigset O; Spina E; Stegman B; Steimer W; Stingl J; Suzen S; Uchida H; Unterecker S; Vandenberghe F; Hiemke C
Other: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2020;108(6):1127-1128
Tribute to Folke Sjoqvist, a Pioneer in Clinical Pharmacology
Dahl M-L; Bergman U; Bertilsson L; Eliasson E; Gustafsson LL; Panagiotidis G; Rane A
Letter: SCHIZOPHRENIA RESEARCH. 2018;199:438-441
Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients
Checa A; Malmqvist A; Flyckt L; Schwieler L; Samuelsson M; Skogh E; Cervenka S; Dahl M-L; Piehl F; Erhardt S; Wheelock CE
Review: OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2015;19(8):435-442
An Appeal to the Global Health Community for a Tripartite Innovation: An "Essential Diagnostics List," "Health in All Policies," and "See-Through 21^st Century Science and Ethics"
Dove ES; Barlas IO; Birch K; Boehme C; Borda-Rodriguez A; Byne WM; Chaverneff F; Coskun Y; Dahl M-L; Dereli T; Diwakar S; Elbeyli L; Endrenyi L; Eroglu-Kesim B; Ferguson LR; Gungor K; Gursoy U; Hekim N; Huzair F; Kaushik K; Kickbusch I; Kiroglu O; Kolker E; Kononen E; Lin B; Llerena A; Malhan F; Nair B; Patrinos GP; Sardas S; Sert O; Srivastava S; Steuten LMG; Toraman C; Vayena E; Wang W; Warnich L; Ozdemir V
Letter: CLINICAL PHARMACOKINETICS. 2015;54(3):321
Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure: Authors' Reply
Lindh JD; Chang M; Tybring G; Dahl M-L
Review: CLINICAL PHARMACOKINETICS. 2014;53(9):801-811
Impact of Cytochrome P450 2C19 Polymorphisms on Citalopram/Escitalopram Exposure: A Systematic Review and Meta-Analysis
Chang M; Tybring G; Dahl M-L; Lindh JD
Review: PHARMACOGENOMICS. 2013;14(11):1319-1336
Pharmacogenetics of olanzapine metabolism
Soderberg MM; Dahl M-L
Letter: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 2012;32(2):287-289
Interindividual Variation in Olanzapine Concentration Influenced by UGT1A4 L48V Polymorphism in Serum and Upstream FMO Polymorphisms in Cerebrospinal Fluid
Mao M; Skogh E; Scordo MG; Dahl M-L
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2010;20:S469
Olanzapine in serum and cerebrospinal fluid in patients with schizophrenia or schizoaffective disorder
Skogh E; Sjodin I; Josefsson M; Dahl ML
Review: PHARMACOGENOMICS. 2008;9(5):625-637
Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms.
Gunes A; Dahl M-L
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:s531-s532
Impact of CYP3A4 polymorphisms on donepezil plasma levels and therapeutic outcome
Scordo MG; Villa LM; Miglio G; Lombardi G; Dahl ML
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S452-S453
Association between a 5HT2C receptor haplotype and metabolic abnormalities in patients treated with olanzapine
Gunes A; Melkersson KI; Scordo MG; Dahl ML
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:s434
Genetic polymorphisms as indicators of response to antipsychotics
Alenius M; Hammarlund-Udenaes M; Wadelius M; Dahl ML; Hartvig P; Lindstroem L
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S307-S308
Taurine in plasma and CSF - a study in healthy male volunteers
Nordin C; Dahl ML; Gupta RC; Samuelsson M
Review: COCHRANE DATABASE OF SYSTEMATIC REVIEWS. 2007;2007(1):CD002216
Therapeutic monitoring of antiepileptic drugs for epilepsy
Tomson T; Dahl ML; Kimland E
Review: PHARMACOGENOMICS. 2006;7(8):1199-1210
Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness?
Ozdemir V; Gunes A; Dahl M-L; Scordo MG; Williams-Jones B; Someya T
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2006;16:s478-s479
Impact of Apo-E genotype on the response to donepezil therapy in patients with Alzheimer's disease
Scordo MG; Varsaldi F; Arena MG; Villa ML; Lombardi G; Cordici E; Dahl ML
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2006;16:s24
Dopamine D2 and D3 receptor gene polymorphisms and clinical outcome of risperidone therapy in schizophrenic patients
Gunes A; Scordo MG; Spina E; Dahl ML
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2005;15:s61-s62
Clinical impact of CYP2D6 polymorphism in patients with Alzheimer's disease in therapy with donepezil
Scordo MG; Varsaldi F; Miglio G; Villa ML; Biolcati A; Dahl ML; Lombardi G
Visa fler

Anställningar

Professor/Överläkare, Klinisk farmakologi, Laboratoriemedicin, Karolinska Institutet, 2012-

Examina och utbildning

Docent, Klinisk farmakologi, Karolinska Institutet, 1992

Handledning

Handledning till doktorsexamen
- Christabel Khaemba, Pharmacovigilance in mass drug administration for the control and elimination of lymphatic filariasis in Kenya, 2024
- Tigist Dires Gebreyesus, Pharmacovigilance of preventive chemotherapy for the control of schistosomiasis and soil-transmitted helminths in Ethiopia, 2023

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Handledning

Handledning till doktorsexamen

Nyheter från KI

Kalenderhändelser från KI